Could a patent get in between you and a Covid-19 test? Yes
Share
In 2001, the United States faced a credible threat of an anthrax outbreak, yet Bayer refused to license its patents on ciprofloxacin (Cipro), the most effective antibiotic treatment for anthrax, to competitors, even as Bayer itself struggled to supply the nation’s antibiotic stockpile.Featured Publications
Lexington, Concord, and the Battle to Keep Government in Check
Low-Energy Fridays: What’s the deal with showerheads?
When the Trail Runs Cold: How Resource Gaps Leave Families Waiting
Antitrust Update: Big Tech Animus May Trump Consumer Welfare
Contraception Annual Supply: How to Implement Policy Successfully